Effects of chronic diseases and polypharmacy on death anxiety Polypharmacy on death anxiety

Basit Öğe Kaydı
dc.contributor.authorKorkut, Burcu
dc.contributor.authorSevinc, Nergiz
dc.date.accessioned2024-09-29T16:09:35Z
dc.date.available2024-09-29T16:09:35Z
dc.date.issued2021
dc.departmentKarabük Üniversitesien_US
dc.description.abstractAim: Chronic diseases and polypharmacy are medical conditions that have negative effects on quality of life and mental state. The aim of this study is to investigate the effects of chronic diseases and the use of multiple concurrent medications on death anxiety within the context of sociodemographic characteristics. Material and Methods: This cross-sectional study included 324 individuals aged between 18-75 years who applied to Karabuk Community Health Center between November 2020 and February 2021. Twelve questions were asked to evaluate the socio-demographic characteristics of the participants. Participants' death anxiety levels were evaluated with the Turkish death anxiety scale consisting of 20 questions. The questionnaire and scale were applied to the participants by face-to-face interview technique. Results: The average age of the participants was 43.6113.27 years. The average death anxiety scale score of the individuals was found to be 47.0111.63. Individuals aged 51 and over, women with 2 or more children, those with hypertension and osteoporosis due to chronic diseases, and participants who use 4 or more drugs per day had significantly higher levels of death anxiety (p<0.05). Discussion: The death anxiety scale score obtained as a result of this study was found to be moderate. Organizing training on death anxiety, which impairs the quality of life of individuals, may positively affect individuals and cause them to become attached to life. Making the necessary changes to healthy lifestyles, early detection of common diseases and taking precautions, and avoiding multiple drug treatments as much as possible may be beneficial in increasing the quality of life and reducing death anxiety.en_US
dc.identifier.doi10.4328/ACAM.20750
dc.identifier.endpageS342en_US
dc.identifier.issn2667-663X
dc.identifier.startpageS338en_US
dc.identifier.urihttps://doi.org/10.4328/ACAM.20750
dc.identifier.urihttps://hdl.handle.net/20.500.14619/7634
dc.identifier.volume12en_US
dc.identifier.wosWOS:000731635500019en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherBayrakol Medical Publisheren_US
dc.relation.ispartofAnnals of Clinical and Analytical Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic Diseaseen_US
dc.subjectDeath Anxiety Scaleen_US
dc.subjectPolypharmacyen_US
dc.titleEffects of chronic diseases and polypharmacy on death anxiety Polypharmacy on death anxietyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu